Dr. David Eichenbaum, Dr. Dilsher Dhoot, Prof. Peter Campochiaro, Dr. Timothy Y Y Lai, 20200904062030
Intravitreal injection of antiangiogenic agents is the standard of care for neovascular age-related macular degeneration (nAMD), however, frequent injections represent a considerable treatment burden for patients. Results of the Ladder and Archway studies, presented at the 38th Annual Meeting of the American Society of Retina Specialists (ASRS 2020), showed that administration of ranibizumab through a port delivery system (PDS) considerably reduced treatment burden, while maintaining comparable efficacy and safety vs intravitreal injections. In an interview with MIMS Doctor, Dr Timothy Lai of Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, discusses how PDS may transform the management of nAMD.